Search Results

240 results for dgse

Stocks on the Launchpad: The Next 3 Market Sensations

Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments

3 Under-the-Radar Cryptos With the Most Moonshot Potential

As the crypto market is experiencing high turbulence ahead of Bitcoin halving, these coins have good basis for becoming moonshot cryptos.

A Healthy Dose of Reality

Every now and then my hometown team, the Seattle Mariners, and the shares of large companies behave similarly. Volume has been light as the market…

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

7 Dividend Stocks Every Investor Should Own to Survive a Market Crash

Buying dividend stocks for retirement is an excellent way to protect your portfolio in the event of a recession or depression.

Monday’s Apple Rumors: A ‘Daily’ Dose

The company’s daily newspaper collaboration with News Corp. looks to be on track for a mid-January release.

XLV Provides a Healthy Dose of Pfizer

If the health care sector is a must-have for your portfolio, and Pfizer is at the top of that list — here’s a way to…

3 Stocks to Turn $1,000 Into $1 Million: February 2024

3 Under-the-Radar Stocks Set to Soar 300% by 2026

Uncover the potential of three under-the-radar stocks for 300% growth by 2026, spanning tech, biotech and energy sectors.

3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024

Predicting top sectors isn’t easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising.

Get a Dose of Innovative Science With Mind Medicine

MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments.

Wall Street Slapped With a Cold Dose of Reality

Stocks suffered their worst day in months Thursday as North Korean headlines continued to weigh on the Dow. What to watch for now? Market breadth.

Trade of the Day: Real Goods Solar (RGSE)

Colorado-based Real Goods Solar (RGSE) flashed as a potential bullish play in the solar space.

For Biopharma Ocugen, Think Speculation In Small Doses

While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success.

Dish Bids for Sprint But Needs Dose of Reality

Charlie Ergen — CEO of Dish Network — is taking a huge gamble with his recent unsolicited bid for Sprint, as the deal only sounds…

Upstart Stock Is Getting a Dose of Reality With Another Downgrade

UPST stock is proving very volatile as analysts sour on its prospects and pile on with price downgrades as the economy shifts.

Microsoft (MSFT) Offers a Double Dose of Good News

Microsoft has announced board changes as well as a dividend increase.

Zynga’s Job Cuts Another Sobering Dose of Reality

Zynga is cutting 520 jobs and closing three offices as the company’s user numbers continue to disappoint.

JPMorgan Earnings Preview — Expect a Hard Dose of Reality

Investors expect ugly earnings and a subsequent drop in stock, and they’ll probably get it — but JPMorgan could do some good with its report.

The 3 Most Promising Stocks to Invest in Before They Take Off

Sponsored by potential FED interest rate cuts, these are the top stocks to invest in before they take off later this year.

7 Cyclical Penny Stocks Best Positioned for 2024 

Cyclical penny stocks offer a double dose of upside potential for risk-seeking investors willing to take a chance for big gains.

3 Healthcare Stocks for Retirement Investors

Medical costs keep on rising. For investors in retirement, a dose of healthcare stocks could be the key to dealing with those costs.

FDA Win Sends Celsion Corporation (CLSN) Shares Higher

Celsion (CLSN) shares were up Thursday as the company received FDA clearance on its plans to start a Phase I/II clinical trial of OVATION II.

Pfizer’s Covid-19 Vaccine Delay Isn’t Welcome News for Shareholders

The UK’s chief medical officers want to delay second doses of the Pfizer/BioNTech vaccine. Is this much ado about nothing for PFE stock?

3 – 10 of 240 results